The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2'-Deoxy-3'-thiacytidine and a reduced ability to synthesize viral DNA

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 8, 1998, Pages 2128-2131

  Ladner, Stephanie K ^a   Miller, Thomas J ^a   King, Robert W ^a,b  

^a Avid Therapeutics Inc   (United States)

^b DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DNA POLYMERASE; ISOLEUCINE; LAMIVUDINE; METHIONINE; VALINE; VIRUS DNA; VIRUS ENZYME; VIRUS RNA;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING SITE; CELL STRAIN HEPG2; CONTROLLED STUDY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; LIVER TRANSPLANTATION; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 0031927319     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.8.2128     Document Type: Article

References (12)

1. Bartholomew, M. M., R. W. Jansen, L. J. Jeffers, K. R. Reddy, L. C. Johnson, H. Bunzenddahl, L. D. Condreay, A. G. Tzakis, E. R. Schiff, and N. A. Brown. 1997. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349:20-22.
2. Deinstag, J. L., R. P. Perrillo, E. F. Schiff, M. Bartholomew, C. Vicary, and M. Rubin. 1995. A preliminary trial of 3TC for chronic hepatitis B infection. N. Engl. J. Med. 333:1657-1661.
3. Fallows, D. A., and S. P. Goff. 1995. Mutations in the ε sequences of human hepatitis B virus affect both RNA encapsidation and reverse transcription. J. Virol. 69:3067-3073.
4. Gao, Q., Z. Gu, J. Hiscott, G. Dionne, and M. A. Wainberg. 1993. Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2′,3′-dideoxycytidine and 2′,3′-dideoxythiacytidine. Antimicrob. Agents Chemother. 37:130-133.
5. Grellier, L., D. Mutimer, M. Ahmed, D. Brown, A. K. Burroughs, K. Tolles, P. McMaster, P. Beranek, F. Kennedy, H. Kibbler, P. McPhillips, E. Elias, and G. Dusheiko. 1996. 3TC prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 348:1212-1215.
6. Ladner, S. K., M. J. Otto, C. S. Barker, K. Zaifert, G.-H. Wang, J.-T. Guo, C. Seeger, and R. W. King. 1997. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob. Agents Chemother. 41:1715-1720.
7. Ladner, S. K., T. J. Miller, M. J. Otto, and R. W. King. 1998. The M539V polymerase variation responsible for 3TC-resistance also confers cross-resistance to other nucleoside analogs. Antiviral Chem. Chemother. 9:65-72.
8. Lai, C.-H., C.-K. Ching, A. K.-M. Tung, E. Li, J. Young, A. Hill, B. C.-Y. Wong, J. Dent, and P.-C. Wu. 1997. 3TC is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 25:241-244.
9. Ling, R., D. Mutimer, M. Ahmed, E. Boxall, E. Elias, M. Dusheiko, and T. J. Harrison. 1996. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with 3TC. Hepatology 24:711-713.
10. Schinazi, R. F., R. M. Lloyd, Jr., M.-H. Ngyen, D. L. Cannon, A. McMillan, N. Ilksoy, C. K. Chu, D. C. Liotta, H. Z. Bazmi, and J. W. Mellors. 1993. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37:875-881.
11. Tipples, G. A., M. M. Ma, K. P. Fischer, V. G. Bain, N. M. Kneteman, and K. L. J. Tyrrell. 1996. Mutation in HBV RNA-dependent DNA polymerase confers resistance to 3TC in vitro. Hepatology 24:714-717.
12. Tisdale, M., S. D. Kemp, N. M. Parry, and B. A. Ladner. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5633-5656.